CLIA Kit for Parathyroid Hormone (PTH) Rattus norvegicus (Rat) Competition CLIA

iPTH; Intact Parathyroid Hormone; Parathormone; Parathyrin

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Parathyroid Hormone (PTH) Packages (Simulation)
  • CLIA Kit for Parathyroid Hormone (PTH) Packages (Simulation)
  • CLIA Kit for Parathyroid Hormone (PTH) Results demonstration
  • CCA866Ra.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Parathyroid Hormone (PTH) and the recovery rates were calculated by comparing the measured value to the expected amount of Parathyroid Hormone (PTH) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 80-89 83
EDTA plasma(n=5) 89-99 96
heparin plasma(n=5) 82-93 85

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Parathyroid Hormone (PTH) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Parathyroid Hormone (PTH) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Parathyroid Hormone (PTH) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-104% 88-95% 78-91% 96-105%
EDTA plasma(n=5) 87-101% 98-105% 90-102% 92-101%
heparin plasma(n=5) 91-105% 93-102% 89-103% 88-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
7. Read RLU value immediately.

CLIA Kit for Parathyroid Hormone (PTH)

Test principle

The microplate provided in this kit has been pre-coated with a monoclonal antibody specific to Parathyroid Hormone (PTH). A competitive inhibition reaction is launched between biotin labeled Parathyroid Hormone (PTH) and unlabeled Parathyroid Hormone (PTH) (Standards or samples) with the pre-coated antibody specific to Parathyroid Hormone (PTH). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Parathyroid Hormone (PTH) in the sample. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is reverse proportional to the Parathyroid Hormone (PTH) level in the sample or standard.

Citations

  • Elevation of PTH and PTHrp Induced by Excessive Fluoride in Rats on a Calcium-deficient DietPubMed: 19915804
  • Effects of duodenal redox status on calcium absorption and related genes expression in high-fat diet–fed miceScienceDirect: S0899900709004808
  • Effects of a Low Calcium Diet and Oxalate Intake on Calcium Deposits in Soft Tissues and Bone Metabolism in Ovariectomized RatsKoreaMed: source
  • Whole body vibration is a safe exercise training method and induces no impaired alterations on rat plasma parametersPubmed: 22173025
  • The effect of supplementation of calcium, vitamin D, boron, and increased fluoride intake on bone mechanical properties and metabolic hormones in rat PubMed: 22782709
  • Effect of consumption of fatty acids, calcium, vitamin D and boron with regular physical activity on bone mechanical properties and corresponding metabolic hormones in rats.PubMed: 22439438
  • Is Gastrectomy-Induced High Turnover of Bone with Hyperosteoidosis and Increase of Mineralization a Typical Osteomalacia?PubMed: PMC3679169
  • Effect of the “protein diet” and bone tissue.Pubmed: 24483972
  • Zoledronic acid has differential anti-tumour activity in the pre-and post-menopausal bone microenvironment in vivoAacrjournals: Source
  • Effect of the “protein diet” and bone tissueAulamedica: Source
  • Effect of whole body vibration on healthy rat plasma parametersEbscohost: Source
  • Biomarkers identified by urinary metabonomics for noninvasive diagnosis of nutritional ricketsPubmed:25051233
  • An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic CancerPubMed: 26266370
  • The Impact of Different Amounts of Calcium Intake on Bone Mass and Arterial Calcification in Ovariectomized RatsPubMed: 26639847
  • Effects of Oryza sativa L. Aleurone Layer Extract on Bone Mineral Density and Bone-related Markers in the Ovariectomized RatArticle: Hksobf_2015_V46N2_167
  • Fat and Sucrose Intake Induces Obesity‐Related Bone Metabolism Disturbances: Kinetic and Reversibility Studies in Growing and Adult RatsPubmed:26175082
  • Cell-matrix signals specify bone endothelial cells during developmental osteogenesis.pubmed:28218908
  • Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting.pubmed:27442254
  • Effects of fatty acids, nutrients and whole body vibration on bone histomorphometry, mechanical properties and metabolic parameters in male rat10.22192/ijarbs.2017.04.04.018
  • Chronic nicotine exposure reduces klotho expression and triggers different renal and hemodynamic responses in -haploinsufficient micePubmed:29363324
  • Dietary supplementation for Santa Inês hair ewes on pasture at pre-and postpartum periods: dry matter intake, digestibility, milk production, and mineral metabolismPubmed:29931604
  • CD8+ T lymphocytes enhance the anabolic effect of intermittent parathyroid hormone on cementoblastsPubmed: 31679847
  • A New Therapeutic Approach Using a Calcilytic (AXT914) for Post-Surgical Hypoparathyroidism in Female RatsPubmed: 32852547
  • Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts.
  • PREVENTIVE AND/OR THERAPEUTIC AGENT FOR OSTEOGENESIS IMPERFECTA AND OTHER DISEASES
  • Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats34373766
  • Correction of a knock-in mouse model of acrodysostosis with gene therapy using a rAAV9-CAG-human PRKAR1A vector34599290
  • Calreticulin Shortage Results in Disturbance of Calcium Storage, Mitochondrial Disease, and Kidney InjuryPubmed:35456008
  • Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease

Recommend products